World

In a stormy week for American equities, Warren Buffett’s Berkshire Hathaway has emerged resilient, outshining the broader market’s plummet. This resilience underscores a deep-rooted trust in Buffett’s strategy, especially during turbulent times propelled by unpredictable political maneuvers such as President Donald Trump’s aggressive tariff policies. While Berkshire’s Class B shares did fall by 6.2%, this
0 Comments
In an audacious move that has sent shockwaves through the global markets, President Donald Trump’s latest tariff strategy has spiraled from a precarious gamble to absolute chaos. The expectation that the tariffs could pose a manageable threat to the economy has dissolved into the harsh reality of unbridled economic repercussions. Initially considered a mere hiccup,
0 Comments
The landscape of global trade is convoluted, characterized by a constant tug-of-war between major economies. The initiation of enhanced tariffs by the U.S. against China marks a pivotal moment in this saga, evoking a multifaceted response from Beijing. Analysts nestled within Greater China provide compelling insights into how China plans to navigate this turbulent chapter
0 Comments
The recent announcement from President Trump regarding sweeping tariffs has sent shockwaves through the U.S. stock market, a move that may well be classified as incompetent governance. With tariffs starting at no less than 10%, the potential for a global trade war looms ominously. For a country that is already dealing with the repercussions of
0 Comments
The recent decision by the U.S. government to impose a staggering 25% tariff on automobile imports has ignited a firestorm of anxiety among Asian automakers, threatening to upend their fragile ecosystems. President Trump’s sweeping tariffs, aimed directly at vehicles “not made in the U.S.,” have sent stock prices tumbling, particularly for major players like Toyota
0 Comments
With its eyes set on revolutionizing the obesity treatment landscape, Novo Nordisk recently found itself grappling with underwhelming clinical trial results for its highly anticipated drug, CagriSema. The enthusiasm surrounding CagriSema—a combination of the amylin analog cagrilintide and the established GLP-1 medication semaglutide—emphasized the pharmaceutical company’s goal of outshining its competitors, most notably Eli Lilly’s
0 Comments